Central Region, Central, Singapore NUS Technology Holdings is the famous Corporate Investor, which was founded in 1995. The main department of described Corporate Investor is located in the Singapore. The company was established in Asia in Singapore.
The usual cause for the fund is to invest in rounds with 6 partakers. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures Southeast Asia & India, Vertex Ventures, Spring SEEDS Capital.
Among the most successful fund investment fields, there are Biotechnology, Health Diagnostics. Among the most popular portfolio startups of the fund, we may highlight Clearbridge Biomedics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Singapore.
The fund is generally included in less than 2 deals every year. Deals in the range of 5 - 10 millions dollars are the general things for fund. The average startup value when the investment from NUS Technology Holdings is 5-10 millions dollars. The important activity for fund was in 2013.
| Fund Name | Location |
| Anhui Xinhua Media | Anhui, China, Hefei |
| Cascadia Partners | Oregon, Portland, United States |
| Cognosante | Mclean, United States, Virginia |
| Future Home Capital | - |
| Honda Xcelerator | California, Mountain View, United States |
| Kun Lun Stone Capital | China, Guangdong, Shenzhen |
| Kyodo Printing | Japan, Tokyo |
| Mavericks Founders | Berlin, Berlin, Germany |
| New Science Ventures | New York, New York, United States |
| NexGen Energy | British Columbia, Canada, Vancouver |
| Nordic Angel Program | - |
| One Team Collective | - |
| Q Investments | Fort Worth, Texas, United States |
| ShengJing360 | Beijing, Beijing, China |
| SZHTI Group | China, Guangdong, Shenzhen |
| Tengram Capital Partners | Connecticut, United States, Westport |
| TriplePoint Ventures | California, Menlo Park, United States |
| Varsity Ventures | California, Stanford, United States |
| Vivo Capital | California, Palo Alto, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Allozymes | $15M | 07 Aug 2023 | Singapore, Central, Singapore | ||
Biolidics | $6M | 13 Mar 2013 | Central |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Allozymes | $15M | 07 Aug 2023 | Singapore, Central, Singapore | ||
Biolidics | $6M | 13 Mar 2013 | Central |
